Franciscan Quality Indicators
Transcription
Franciscan Quality Indicators
Franciscan Quality Indicators A guide to Centers for Medicare & Medicaid Services/ The Joint Commission quality measures including Value Based Purchasing Version 5.0 (Revised January, 2013) How to Use This Booklet Please review this booklet and keep it as a reference for providing care to patients who are being treated for the conditions indicated. The booklet summarizes important sections from the CMS Specifications Manual and other FHS-specific information. The Centers for Medicare & Medicaid Services (CMS), along with public and private health care stakeholders, are working to streamline and standardize hospital quality and safety performance and reporting. This trend presents a valuable opportunity for Franciscan hospitals to refocus our efforts to provide the best quality, best practices and best care to our patients. Quality of care typically is determined through a set of uniform, national hospital quality measures which focus on a limited number of high-volume inpatient conditions. The standard measures are described inside this booklet. CMS has introduced “value-based purchasing” (VBP) to encourage hospitals to follow these national standards by linking reimbursement to quality performance. In this booklet, you will see the VBP symbol next to quality measures that are currently included in the CMS value-based purchasing program. More measures are expected to be added in the near future. Excellent performance in these measures has been shown to produce the greatest impact on quality improvement. Quality indicators are reassessed and revised frequently; visit www.FHShealth.org/QCE/CMSspecs.asp for the latest information. Table of Contents: Medical Quality Indicators Overview Emergency Department Quality Indicators Hospital-Acquired Conditions (HACs) Hospital Consumer Assessment of Healthcare Providers and System (HCAHPS) Survey Pneumonia Antibiotic Recommendations for Non-ICU/PCU Patients and ICU/PCU Patients Surgical Care Improvement Project (SCIP) Quality Indicators Surgical Care Improvement Project – Inpatient Preoperative Antibiotic Prophylaxis Guidelines Surgical Care Improvement Project – Outpatient Preoperative Antibiotic Prophylaxis Guidelines Surgical Care Improvement Project – Venous Thromboembolism (VTE) Prophylaxis Options for Surgery Education Form: Inpatient Acute Myocardial Infarction (AMI) Education Form: Inpatient Heart Failure (HF) Education Form: Left Ventricular Systolic Function (LVSF) Assessment Inclusion Table 1.2 Education Form: Immunizations Education Form: Inpatient Surgical Care Improvement Project (SCIP) Education Form: Inpatient Venous Thromboembolism (VTE) Education Form: Stroke 1-2 3 4 5-7 8 9 10 11-12 13-14 15-16 17-18 19 20 21-23 24-25 26-27 Franciscan Medical Quality Indicators CMS/The Joint Commission Medical Quality Indicators Overview (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) ACUTE MYOCARDIAL INFARCTION • • • • • • • • AMI-1 Aspirin at arrival* AMI-2 Aspirin prescribed at discharge* AMI-3 ACEI or ARB at discharge for left ventricular systolic dysfunction (EF < 40%)* AMI-5 Beta-blocker at discharge AMI-8a PCI within 90 minutes of hospital arrival VBP AMI-10 Statin prescribed at discharge* VBP AMI 30-day risk standardized readmission measure (Medicare patients) AMI 30-day risk standardized mortality rate (Medicare patients) VBP HEART FAILURE • • • • • HF-1 Discharge instructions include instructions regarding activity, diet, follow-up care, medications, symptoms worsening, and weight monitoring VBP HF-2 Left ventricular function assessment HF-3 ACEI or ARB at discharge for left ventricular systolic dysfunction (EF < 40%)* Heart failure 30-day risk standardized readmission measure (Medicare patients) Heart failure 30-day risk standardized mortality rate (Medicare patients) VBP PNEUMONIA • • • • • • • PN-3a Blood cultures for patients admitted or transferred to ICU within 24 hours of arrival PN-3b Blood cultures performed prior to initial antibiotic when blood culture collected in the emergency department VBP PN-6 Initial antibiotic selection–overall VBP PN-6a Initial antibiotic selection for immunocompetent ICU patients PN-6b Initial antibiotic selection for immunocompetent non-ICU patients Pneumonia 30-day risk standardized readmission measure (Medicare patients) Pneumonia 30-day risk standardized mortality rate (Medicare patients) VBP IMMUNIZATIONS • IMM-1 Pneumococcal Immunization • IMM-2 Influenza Immunization Quality indicators are reassessed and revised on a continual basis. For the most current information, please visit the CMS QualityNet Specifications Manual website: www.FHShealth.org/QCE/CMSspecs.asp * If contraindicated, document reasoning/condition. Clinical Effectiveness Department Version 5.0, Revised: 1-2013 1 Franciscan Medical Quality Indicators CMS/The Joint Commission Medical Quality Indicators Overview (page 2) (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Inpatient Venous Thromboembolis (VTE) • • • • • • VTE-1 Venous Thromboembolism Prophylaxis VTE-2 Intensive Care Unit Venous Thromboembolism Prophylaxis VTE-3 Venous Thromboembolism Patients with Anticoagulation Overlap Therapy VTE-4 Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages / Platelet Count Monitoring by Protocol or Nomogram VTE-5 Venous Thromboembolism Warfarin Therapy Discharge Instructions VTE-6 Hospital Acquired Potentially-Preventable Venous Thromboembolism STROKE • • • • • • • STK-1 Venous Thromboembolism (VTE) Prophylaxis STK-2 Discharged on Antithrombotic Therapy STK-3 Anticoagulation Therapy for Atrial Fibrillation/Flutter STK-4 Thrombolytic Therapy STK-5 Antithrombotic Therapy by End of Hospital Day 2 STK-6 Discharged on Statin Medication STK-10 Assessed for Rehabilitation Quality indicators are reassessed and revised on a continual basis. For the most current information, please visit the CMS QualityNet Specifications Manual website: www.FHShealth.org/QCE/CMSspecs.asp * If contraindicated, document reasoning/condition. 2 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Medical Quality Indicators CMS/The Joint Commission EMERGENCY DEPARTMENT QUALITY INDICATORS Inpatient ED (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) • ED-1 Median time from ED arrival to ED departure for admitted patients • ED-2 Admit decision time to ED departure time for admitted patients Outpatient ED (Hospital OQR Specifications Manual 6.0b—Discharges between 1-1-13 and 12-31-13) • • • • • • • • • • OP-1 Median time to fibrinolysis OP-2 Fibrinolytic therapy received within 30 minutes of ED arrival OP-3 Median time to transfer to another facility for acute coronary intervention OP-4 Aspirin at arrival OP-5 Median time to ECG OP-18 Median time from ED arrival to ED departure for discharged ED patients OP-20 Door to diagnostic evaluation by a qualified medical personnel OP-21 Median time to pain management for long bone fracture OP-22 Left without being seen OP-23 Head CT or MRI scan results for acute ischemic stroke or hemorrhagic stroke patients who received head CT or MRI scan interpretation within 45 minutes of ED arrival Quality indicators are reassessed and revised on a continual basis. For the most current information, please visit the CMS QualityNet Specifications Manual website: www.FHShealth.org/QCE/CMSspecs.asp Clinical Effectiveness Department Version 5.0, Revised: 1-2013 3 Franciscan Medical Quality Indicators CMS/The Joint Commission Hospital-Acquired Conditions (HACs) and Present on Admission (POA) Indicator Reporting For discharges occurring on or after October 1, 2008, Inpatient Prospective Payment System (IPPS) hospitals will not receive additional payment for cases when one of the selected complicating conditions is acquired during hospitalization (i.e., was not present on admission). Present on Admission (POA) is defined as present at the time the order for inpatient admission occurs—conditions that develop during an outpatient encounter, including ED, observation or outpatient surgery, are considered POA. If at discharge, there is a selected complicating condition that was not identified as POA, it is considered a hospital-acquired condition. The healthcare provider who is legally accountable for the patient must document POA before discharge. The importance of consistent, complete documentation in the medical record cannot be overemphasized. Hospital-Acquired Conditions (HACs)* • • • • • • • • • Deep Vein Thrombosis and Pulmonary Embolism following Certain Orthopedic Procedures • Total Knee Replacement • Hip Replacement Foreign Object Retained After Surgery Air Embolism Blood Incompatibility Pressure Ulcer Stages III & IV Falls and Trauma • Fracture • Dislocation • Intracranial Injury • Crushing Injury • Burn • Electric Shock Catheter-Associated Urinary Tract Infection (CAUTI) Vascular Catheter-Associated Infection Iatrogenic Pneumothorax with Venous Catheterization • • • • • Manifestations of Poor Glycemic Control • Diabetic Ketoacidosis • Nonketotic Hyperosmolar Coma • Hypoglycemic Coma • Secondary Diabetes with Ketoacidosis • Secondary Diabetes with Hyperosmolarity Surgical Site Infection, Mediastinitis, following Coronary Artery Bypass Graft (CABG) Surgical Site Infection following Cardiac Implantable Electronic Device (CIED) Surgical Site Infection following Certain Orthopedic Procedures • Spine • Neck • Shoulder • Elbow Surgical Site Infection following Bariatric Surgery for Obesity • Laparoscopic Gastric Bypass • Gastroenterostomy • Laparopscopic Gastric Restrictive Surgery *As specified as statue, CMS may revise the list of conditions from time to time, as long as it contains at least two conditions 4 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Medical Quality Indicators CMS/The Joint Commission HCAHPS (“H-caps”) Hospital Consumer Assessment of Healthcare Providers and Systems The HCAHPS survey is a standardized national survey implemented by CMS. The survey contains 40 questions that encompass 8 major composites measuring a patient’s perception of care received during his or her inpatient stay and the understanding of care needed after discharged from the hospital. The survey asks about the aspects of the patient experience that, based on research, are directly connected with health outcomes. The survey administered by phone to a random sample of adult, discharged patients who had been treated for a range of medical conditions, including maternity services. The 8 composite scores are currently included in the CMS value-based purchasing (VBP) program. The inpatient survey sets a high bar for responses, with only the highest or “top box” responses counting in the VBP scoring algorithm. The “top box” score is the best score on the scale (i.e., always, yes, 9 or 10, definitely yes). For example, the top box composite score for “Doctor Communication” measures the percentage of patients who answered their doctor was always courteous and respectful, listened carefully, and explained things in a way that was understood. The survey is designed to produce comparable data to allow for objective and meaningful comparisons among hospitals and to create incentives for hospitals to improve quality of care. The aim is to consistently score top-box rating in each major composite. AIDET is an evidence-based practice shown to improve patient perception of care when used appropriately with every patient every time. AIDET means Acknowledging the patient and loved ones with eye contact and a smile, Introducing yourself and your colleagues, providing information about the Duration of wait times and procedures, providing Explanations why and Thanking patients and family members at the end of each encounter. INPATIENT HCAHPS SURVEY QUESTIONS *Top Box Score Doctor Communication VBP *4=Always, 3=Usually, 2=Sometimes, 1=Never During this hospital stay, how often did doctors treat you with courtesy and respect? During this hospital stay, how often did doctors listen carefully to you? During this hospital stay, how often did doctors explain things in a way you could understand? Nurse Communication VBP During this hospital stay, how often did nurses treat you with courtesy and respect? During this hospital stay, how often did nurses listen carefully to you? *4=Always, 3=Usually, 2=Sometimes, 1=Never During this hospital stay, how often did nurses explain things in a way you could understand? Clinical Effectiveness Department Version 5.0, Revised: 1-2013 5 Franciscan Medical Quality Indicators CMS/The Joint Commission HCAHPS (page 2) INPATIENT HCAHPS SURVEY QUESTIONS *Top Box Score Responsiveness of staff VBP During this hospital stay, after you pressed the call button, how often did you get help as soon as you wanted it? *4=Always, 3=Usually, 2=Sometimes, 1=Never Environment VBP During this hospital stay, how often were your room and bathroom kept clean? Pain Management VBP During this hospital stay, how often was your pain well controlled? Communication about Medications VBP Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? Discharge instructions VBP During this hospital stay, did doctors, nurses or other hospital staff talk with you about whether you would have the help you needed when you left the hospital? Overall Rating of Hospital VBP Using any number from 0 to 10, where 0 is the worst hospital possible and 10 is the best hospital possible, what number would you use to rate this hospital? During this hospital stay, how often did you get help in getting to the bathroom or in using a bedpan as soon as you wanted? During this hospital stay, how often was the area around your room quiet at night? *4=Always, 3=Usually, 2=Sometimes, 1=Never *4=Always, 3=Usually, 2=Sometimes, 1=Never During this hospital stay, how often did the hospital staff do everything they could to help you with your pain? Before giving you any new medicine, how often did hospital staff describe possible side effects in a way you could understand? *4=Always, 3=Usually, 2=Sometimes, 1=Never *1=Yes, 2=No During this hospital stay, did you get information in writing about what symptoms or health problems to look out for after you left the hospital? Would you recommend this hospital to your friends and family? During this hospital stay, how often did the staff treat you as a whole person, not just a medical condition? *10=Best hospital possible, 0=Worst hospital possible How often did the staff meet your expectations regarding your family's involvement in your care? 6 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Medical Quality Indicators CMS/The Joint Commission HCAHPS (page 3) INPATIENT HCAHPS SURVEY QUESTIONS *Top Box Score New A Hospitalist is a hospital-based doctor who cares for hospitalized patients in the place of a patient’s personal healthcare provider. Did you receive care from a Hospitalist? Yes/No Using any number from 0 to 10, where 0 is the worst possible care and 10 is the best possible care, what number would you use to rate the care received from the hospitalist who treated you? 0-10 Thinking of your hospital stay, what one thing could the hospital have done better? Is there a specific person you would like to see complimented or thanked for the care they provided? NEW Understanding Care When Discharged During this hospital stay, staff took my preferences and those of my family or caregiver into account in deciding what my health care needs would be when I left. 1=Strongly agree 2=Disagree 3=Agree 4=Strongly agree When I left the hospital, I had a good understanding of the things I was responsible for in managing my health. 1=Strongly agree 2=Disagree 3=Agree 4=Strongly agree When I left the hospital, I clearly understood the purpose for taking each of my medications. 1=Strongly agree 2=Disagree 3=Agree 4=Strongly agree 5=I was not given any medication when I left the hospital Clinical Effectiveness Department Version 5.0, Revised: 1-2013 7 Franciscan Medical Quality Indicators CMS/The Joint Commission PNEUMONIA ANTIBIOTIC RECOMMENDATIONS for Non-ICU/PCU Patients and ICU/PCU Patients (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Note: Pharmacy to adjust antibiotic dosing for renal function Patient Type Approved Antibiotics NON-ICU/PCU PATIENT • Doxycycline (PO or IV) + • Ceftriaxone (IV) OR • Azithromycin (PO or IV) + • Ceftriaxone (IV) OR • Levofloxacin (PO or IV) ICU/PCU PATIENT • • • • Ceftriaxone (IV) + Azithromycin (IV) OR Ceftriaxone (IV) + Levofloxacin (IV) For documented B-lactam allergy: • Aztreonam (IV) + • Levofloxacin (IV) NON-ICU/PCU OR ICU/PCU PATIENT WITH PSEUDOMONAL RISK Clearly document pseudomonal risk in the medical record. Pseudomonal risk is defined as having multiple rounds of antibiotics or corticosteroids with documented structural lung disease (i.e., chronic bronchitis, COPD, emphysema). • • • • Piperacillin/Tazobactam (IV) + Levofloxacin (IV) OR Meropenem (IV) + Levofloxacin (IV) For documented B-lactam allergy: • Aztreonam (IV) + • Levofloxacin (IV) RISK SPECIFIC TREATMENTS IF MRSA IS SUSPECTED: IF ASPIRATION IS SUSPECTED: IF PNEUMOCYSTIS PNEUMONIA IS SUSPECTED IN AIDS PATIENT ADD: Vancomycin (IV) ADD: Clindamycin (IV) ADD: Trimethoprim/ sulfamethoxazole (PO or IV) Special Considerations 2nd dose per Pharmacy protocol Not necessary if on Pipercillin/Tazbactam IV per Pharmacy dosing Quality indicators are reassessed and revised on a continual basis. For the most current information, please visit the CMS QualityNet Specifications Manual website: www.FHShealth.org/QCE/CMSspecs.asp 8 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Surgical Quality Indicators CMS/The Joint Commission SURGICAL CARE IMPROVEMENT PROJECT (SCIP) Quality Indicators (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Inpatient • • • • • • • • • INF-1 Prophylactic antibiotic received within one hour prior to surgical incision VBP INF-2 Prophylactic antibiotic selection VBP INF-3 Prophylactic antibiotics discontinued within 24 hours after surgery end time (48 hours for cardiac surgery) VBP INF-4 Cardiac surgery patients with controlled 6 a.m. postoperative serum glucose on Postop Day 1 and Postop Day 2 – (glucose < 200) VBP INF-6 Appropriate hair removal INF-9 Urinary catheter removed on Postop Day 1 or Postop Day 2 VBP INF-10 Surgical patients with perioperative temperature management—forced air warming or temperature ≥ 96.8 CARD-2 Surgical patients on beta-blocker prior to arrival who received betablocker during the perioperative period (24 hours before surgery through Postop Day 2 with day of surgery being Day Zero) VBP VTE-2 Surgery patients who received appropriate venous thromboembolism prophylaxis within 24 hours prior to surgery to 24 hours after surgery VBP OUTPATIENT (CMS Hospital OQR Specifications Manual 6.0—Discharges between 1-1-13 and 12-31-13) • OP-6 Timing of antibiotic prophylaxis • OP-7 Prophylactic antibiotic for surgical patients Quality indicators are reassessed and revised on a continual basis. For the most current information, please visit the CMS QualityNet Specifications Manual website: www.FHShealth.org/QCE/CMSspecs.asp Clinical Effectiveness Department Version 5.0, Revised: 1-2013 9 Franciscan Surgical Quality Indicators CMS/The Joint Commission SURGICAL CARE IMPROVEMENT PROJECT – INPATIENT Preoperative Antibiotic Prophylaxis Guidelines (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Surgery Type Approved Antibiotics Special Considerations CABG, Cardiac, Vascular • Cefazolin • Vancomycin* Hip/Knee Arthroplasty • Cefazolin • Vancomycin* If ß-lactam allergy: • Clindamycin • Vancomycin If ß-lactam allergy: • Clindamycin • Vancomycin Colon • Cefoxitin—1st choice at FHS facilities • Cefazolin + Metronidazole If PCN or ß-lactam allergy: • Metronidazole + Levofloxacin • Metronidazole + Gentamicin • Clindamycin + Gentamicin Hysterectomy, Hysterectomy + Colon** • Cefazolin • Cefoxitin If ß-lactam allergy: • Metronidazole + Gentamicin • Clindamycin + Gentamicin • Metronidazole + Levofloxacin *Vancomycin should be used with caution. Only acceptable with specific documentation of provider justification, such as MRSA colonization or infection, increased MRSA rate related to facility or operation specific, chronic wound care or dialysis, continuous inpatient stay >24 hours prior to procedure, transfer from an inpatient hospitalization after a three-day stay, acute inpatient hospitalization or LTC within last year, or valve surgery. This must be explicitly documented in the medical record with the order. **If Cefazolin used for hysterectomy prior to colon surgery, and redosing is required, redose with Cefoxitin Quality indicators are reassessed and revised on a continual basis. For the most current information, please visit the CMS QualityNet Specifications Manual website: www.FHShealth.org/QCE/CMSspecs.asp 10 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Surgical Quality Indicators CMS/The Joint Commission Surgical Care Improvement Project – Outpatient Preoperative Antibiotic Prophylaxis Guidelines (CMS Specifications Manual 6.0b—Discharges between 1-1-13 and 12-31-13) Surgery Type Approved Antibiotics Special Considerations Cardiac (Pacemakers or AICDs), VASCULAR • Cefazolin • Vancomycin* (acceptable with documented justification for use) If ß-lactam allergy: • Clindamycin • Vancomycin ORTHOPEDIC, PODIATRY Transrectal Prostate Biopsy • Cefazolin • Vancomycin (acceptable with documented justification for use) • • • • • If ß-lactam allergy: • Clindamycin • Vancomycin Cefazolin Ciprofloxacin (may be oral abx.) Cefoxitin Gentamicin + Metronidazole Gentamicin + Clindamycin Penile Prosthesis Insertion, Removal, Revision • Gentamicin + Cefazolin • Gentamicin + Cefuroxime • Gentamicin + Clindamycin PEG Placement, PEG Revision • • • • Cefazolin Cefoxitin Cefazolin + Metronidazole Vancomycin* (acceptable with documented justification for use) If ß-lactam allergy: • Clindamycin ± Gentamicin • Clindamycin ± Ciprofloxacin • Vancomycin ± Ciprofloxacin *Vancomycin should be used with caution. Only acceptable with specific documentation of provider justification, such as MRSA colonization or infection, increased MRSA rate related to facility or operation specific, chronic wound care or dialysis, continuous inpatient stay >24 hours prior to procedure, transfer from an inpatient hospitalization after a three-day stay, acute inpatient hospitalization or LTC within last year, or valve surgery. This must be explicitly documented in the medical record with the order. Clinical Effectiveness Department Version 5.0, Revised: 1-2013 11 Franciscan Surgical Quality Indicators CMS/The Joint Commission Surgical Care Improvement Project – Outpatient preoperative Antibiotic prophyLaxis Options (Page 2) Surgery Type Approved Antibiotics Special Considerations LaparoscopicallyAssisted Hysterectomy and Vaginal Hysterectomy • Cefazolin • Cefoxitin If ß-lactam allergy: • Metronidazole + Gentamicin • Clindamycin + Gentamicin • Metronidazole + Levofloxacin Pubovaginal Sling • Cefazolin • Cefoxitin If ß-lactam allergy: • Metronidazole + Gentamicin • Clindamycin + Gentamicin Head and Neck • Cefazolin • Vancomycin* (acceptable with documented justification for use) If ß-lactam allergy: • Clindamycin • Clindamycin + Gentamicin Neurological • Cefazolin • Clindamycin If ß-lactam allergy: • Clindamycin • Vancomycin *Vancomycin should be used with caution. Only acceptable with specific documentation of provider justification, such as MRSA colonization or infection, increased MRSA rate related to facility or operation specific, chronic wound care or dialysis, continuous inpatient stay >24 hours prior to procedure, transfer from an inpatient hospitalization after a three-day stay, acute inpatient hospitalization or LTC within last year, or valve surgery. This must be explicitly documented in the medical record with the order. Quality indicators are reassessed and revised on a continual basis. For the most current information, please visit the CMS QualityNet Specifications Manual website: www.FHShealth.org/QCE/CMSspecs.asp 12 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Surgical Quality Indicators CMS/The Joint Commission Surgical Care Improvement Project Venous Thromboembolism (VTE) Prophylaxis Options for Surgery (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Surgery Type Recommended Prophylaxis Options* Any of the following: Intracranial Neurosurgery • • • • Intermittent pneumatic compression devices (IPC) with or without graduated compression stockings (GCS) Low-dose unfractionated heparin (LDUH) Low molecular weight heparin (LMWH)† LDUH or LMWH† combined with IPC or GCS General Surgery • • • • Low-dose unfractionated heparin (LDUH) Low molecular weight heparin (LMWH) LDUH or LMWH combined with IPC or GCS Factor Xa Inhibitor Gynecologic Surgery • • • • • Low-dose unfractionated heparin (LDUH) Low molecular weight heparin (LMWH) Factor Xa Inhibitor Intermittent pneumatic compression devices (IPC) LDUH or LMWH combined with IPC or GCS Urologic Surgery • • • • • • Low-dose unfractionated heparin (LDUH) Low molecular weight heparin (LMWH) Factor Xa Inhibitor Graduated compression stockings (GCS) Intermittent pneumatic compression devices (IPC) LDUH or LMWH or Factor Xa Inhibitor combined with IPC or GCS Any of the following with a documented reason for not administering pharmacological prophylaxis** • • Graduated compression stockings (GCS) Intermittent pneumatic compression devices (IPC) * Patients who receive neuraxial anesthesia or have a documented reason for not administering pharmacological prophylaxis may pass the performance measure if pharmacological or mechanical prophylaxis is ordered and received anytime from hospital arrival to 24 hours after anesthesia end time. ** For example, documented high risk of bleeding, active bleeding, thrombocytopenia, patient on continous IV heparin therapy or patient refusal. † Current guidelines recommend postoperative low molecular weight heparin for Intracranial Neurosurgery. Clinical Effectiveness Department Version 5.0, Revised: 1-2013 13 Franciscan Surgical Quality Indicators CMS/The Joint Commission SURGICAL CARE IMPROVEMENT PROJECT VTE PROPHYLAXIS OPTIONS FOR SURGERY (Page 2) Surgery Type Recommended Prophylaxis Options* Any of the following: Any of the following with a documented reason for not administering pharmacological prophylaxis** Elective Hip Replacement: Total, Partial and Revisions • Low molecular weight heparin (LMWH) •Warfarin • Factor Xa Inhibitor • Oral Xa Inhibitor • Intermittent pneumatic compression devices (IPC) • Venous foot pump (VFP) Hip Fracture Surgery • Low-dose unfractionated heparin (LDUH) • Low molecular weight heparin (LMWH) •Warfarin • Factor Xa Inhibitor • • • Elective Knee Replacement: Total and Revisions • Low molecular weight heparin (LMWH) •Warfarin • Intermittent pneumatic compression devices (IPC) • Venous foot pump (VFP) • Oral Xa Inhibitor • Factor Xa Inhibitor • Intermittent pneumatic compression devices (IPC) • Venous foot pump (VFP) Graduated compression stockings (GCS) Intermittent pneumatic compression devices (IPC) Venous foot pump (VFP) * Patients who receive neuraxial anesthesia or have a documented reason for not administering pharmacological prophylaxis may pass the performance measure if pharmacological or mechanical prophylaxis is ordered and received anytime from hospital arrival to 24 hours after anesthesia end time. ** For example, documented high risk of bleeding, active bleeding, thrombocytopenia, patient on continous IV heparin therapy or patient refusal. † The U.S. Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce the risk of blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) following knee or hip replacement surgery ONLY. Quality indicators are reassessed and revised on a continual basis. For the most current information, please visit the CMS QualityNet Specifications Manual website: www.FHShealth.org/QCE/CMSspecs.asp 14 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Medical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m INPATIENT ACUTE MYOCARDIAL INFARCTION (AMI) (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Acute Myocardial Infarction (AMI) QUALITY INDICATORS Explanation and/or contraindications must be documented in the medical record Aspirin at Arrival— Or documented as taken/ given within 24 hours before or after arrival Reasons for not administering include: • Aspirin allergy • Coumadin/warfarin or Pradaxa/dabigatran as pre-arrival medication • Other reasons explicitly documented by Physician/APN/PA or Pharmacist ACEI or ARB at Discharge for LVSD— (LVSD defined as EF< 40% or narrative description of moderate or severe systolic dysfunction) Reasons for not prescribing include: • Documented allergy to both ACEI and ARB • Moderate or severe aortic stenosis • Physician/APN/PA or Pharmacist documentation of BOTH a reason for not prescribing ACEI at discharge AND a reason for not prescribing an ARB at discharge. Note: Documentation of a reason for not prescribing one class (either ACEI or ARB) should be considered implicit documentation of a reason for not prescribing the other class for the following five conditions only: angioedema, hyperkalemia, hypotension, renal artery stenosis, worsening renal function/renal disease/dysfunction. • Reason documented by Physician/APN/PA or Pharmacist for not prescribing an ARB at discharge AND an ACEI allergy • Reason documented by Physician/APN/PA or Pharmacist for not prescribing an ACEI at discharge AND an ARB allergy Note: Reasons for no ACEIs and reasons for no ARBs must be explicitly documented (e.g., "K+5.5—No ACEI") or clearly implied (e.g., “severe hypotension with ACEIs in past, “ “Hx ACEI-induced cough,” “ARBs contraindicated.”) Clinical Effectiveness Department Version 5.0, Revised: 1-2013 15 Franciscan Medical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m INPATIENT ACUTE MYOCARDIAL INFARCTION (AMI) (page 2) ACUTE MYOCARDIAL INFARCTION (AMI) Explanation and/or contraindications must be documented in the medical record Aspirin Prescribed at Discharge Reasons for not prescribing include: • Aspirin allergy • Coumadin/warfarin or Pradaxa/dabigatran prescribed at discharge • Other reasons explicitly documented by Physician/APN/PA or Pharmacist Beta-Blocker Prescribed at Discharge Reasons for not prescribing include: • Beta-blocker allergy • 2nd or 3rd degree heart block (without pacemaker) on ECG on arrival or during hospital stay • Other reasons documented by Physician/APN/PA/Pharmacist—must be explicit (e.g.–”COPD-No BBs”) or clearly implied (e.g.–”BBs contraindicated”) PCI within 90 minutes of hospital arrival System reasons for delay are not acceptable such as equipment or staff unavailability. Reasons for delay include: • Cardiopulmonary arrest • Initial family or patient refusal • Mechanical circulatory assist device insertion • Intubation • Other patient centered reason explicitly documented by physician Statin prescribed at discharge Reasons for not prescribing include: • Statin medication allergy • Other reasons documented by Physician/APN/PA or Pharmacist (e.g.–”Chronic liver failure–Statins contraindicated”) • Hepatic Failure • Hepatitis • Myalgias • Patient/family refusal • Rabdomyolysis 16 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Medical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m INPATIENT HEART FAILURE (HF) (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Heart Failure (HF) QUALITY INDICATORS Explanation and/or contraindications must be documented in the medical record LVF Assessment Documentation of left ventricular systolic function assessment prior to arrival, during hospitalization, planned for after discharge or reason documented by Physician/APN/PA for not assessing. See table 1.2 for complete list of inclusions. Nephrology patients coming in with pulmonary edema of cardiogenic origin will end up in the heart failure population. Please make sure LVF assessment is documented on these patients or explicitly document why LVF is not being assessed (e.g., ”ESRD. Will not measure EF.”) ACEI or ARB at Discharge for LVSD— (LVSD defined as EF< 40% or narrative description of moderate or severe systolic dysfunction) Reasons for not prescribing include: • Documented allergy to both ACEI and ARB • Moderate or severe aortic stenosis • Physician/APN/PA or Pharmacist documentation of BOTH a reason for not prescribing ACEI at discharge AND a reason for not prescribing an ARB at discharge. Note: Documentation of a reason for not prescribing one class (either ACEI or ARB) should be considered implicit documentation of a reason for not prescribing the other class for the following five conditions only: angioedema, hyperkalemia, hypotension, renal artery stenosis, worsening renal function/renal disease/dysfunction. • Reason documented by Physician/APN/PA or Pharmacist for not prescribing an ARB at discharge AND an ACEI allergy • Reason documented by Physician/APN/PA or Pharmacist for not prescribing an ACEI at discharge AND an ARB allergy Note: Reasons for no ACEIs and reasons for no ARBs must be explicitly documented (e.g., “K+5.5—No ACEI”) or clearly implied (e.g., “severe hypotension with ACEIs in past, “ “Hx ACEI-induced cough,” “ARBs contraindicated.”) *LVSF assessment is a measure or left ventricular contractility and may be described either quantitatively or qualitatively (e.g., “left ventricular EF=30%” or “moderate left ventricular systolic dysfunction”). Clinical Effectiveness Department Version 5.0, Revised: 1-2013 17 Franciscan Medical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m INPATIENT HEART FAILURE (HF) (page 2) (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Heart Failure (HF) QUALITY INDICATORS Explanation and/or contraindications must be documented in the medical record Complete Discharge Instructions All six elements must be covered: • Diet • Activity • Discharge medications (medications list on provider discharge summary, discharge medication reconciliation form, and nursing discharge instruction list must match) • Follow-up appointment—cannot state “follow-up as needed.” Needs provider name and date & time of appt if available. •What to do if symptoms worsen specific to heart failure •Weight monitoring 18 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Medical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m Left Ventricular Systolic Function (LVSF) Assessment Inclusion Table 1.2 (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Echocardiogram (echo) • Cardiac ultrasound • Transesophageal echocardiogram (TEE) • Transthoracic echocardiogram (TTE) Cardiac Catheterization (cath) with Left Ventriculogram (LV gram) • Cardiac cath with mention of LVSF • Cardiac/coronary angiogram with LV gram • Cardiac/coronary angiogram with mention of LVSF • Cardiac/coronary arteriogram with LV gram • Cardiac/coronary arteriogram with mention of LVSF • Left heart cath with mention of LVSF • Left ventriculogram (LV gram) Other LVSF Assessment Tests • Cardiac MRI with mention of LVSF • CT scan of chest with mention of LVSF • Multiple gated acquisition scan (MUGA) or other cardiac imaging testing described as gated or blood pool • Other nuclear test (e.g., SPECT, PET) with mention of LVSF Left Ventricular Systolic Function (LVSF) • Akinesis described as left ventricular • Diastolic dysfunction, failure, function or impairment • Dysfunction described as biventricular, left ventricular (LVD, LVSD), systolic or ventricular • Dyskinesis described as left ventricular • Ejection fraction (EF, LVEF) • Endstage cardiomyopathy • Failure described as biventricular, left ventricular, systolic or ventricular • Function described as biventricular, left ventricular (LVF), systolic or ventricular • Hypokinesis described as left ventricular Clinical Effectiveness Department Version 5.0, Revised: 1-2013 19 Franciscan Medical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m Immunizations (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Immunization QUALITY INDICATORS Explanation and/or contraindications must be documented in the medical record Pneumococcal Vaccination—must be assessed and administered when applicable to all patients ≥ 65 years old and ages 5-64 with high risk conditions (i.e., Diabetes, Nephrotic Syndrome, ESRD, CHF, COPD, HIV, Asthma, Aspienia) Reasons for not administering include: • Pneumococcal vaccine was received in the past and this is documented in the medical record for the present episode of care • Documentation of patient or caregiver's refusal of pneumococcal vaccine • Documented allergy/sensitivity to pneumococcal vaccine (reaction must be documented) • Documented bone marrow transplant within the past 12 months • Documentation that patient is currently receiving scheduled course of chemotherapy or radiation during this hospitalization or less than 2 weeks prior • Documentation that patient received shingles vaccine (Zostavax) within last 4 weeks • Patients 5-18 years of age who received a conjugate vaccine within the previous 8 weeks Influenza Vaccination— must be assessed and administered when applicable to all patients 6 months of age and older, regardless of diagnosis, hospitalized (discharged) during the months of September through March Reasons for not administering include: • Influenza vaccine was received in the past (during this flu season) and is documented in the medical record for the present episode of care • Documentation of patient or caregiver's refusal of influenza vaccine • Documented allergy/sensitivity to influenza vaccine (reaction must be documented) • Documented anaphylactic egg allergy • Documented anaphylactic latex allergy • Documented bone marrow transplant within the past 6 months • Documented history of Guillian-Barré syndrome within 6 weeks after a previous influenza vaccination 20 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Surgical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m INPATIENT SURGICAL CARE IMPROVEMENT PROJECT (SCIP) (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) Surgical Care Improvement Project (SCIP) QUALITY INDICATORS Explanation and/or contraindications must be documented in the medical record Appropriate VTE (Venous Thromboembolism) Prophylaxis received Patient must receive appropriate VTE prophylaxis according to current recommendations. See VTE Prophylaxis Options for Surgery for listing of current recommendations by surgery type. Most surgeries require a pharmacologic prophylaxis agent such as low molecular weight heparin (LMWH) or low-dose unfractionated heparin (LDUH) unless there are documented reasons for not administering pharmacologic prophylaxis. Orders to hold prophylaxis without a documented reason or contraindication does not meet the compliance requirement for this indicator. Reasons for not administering pharmacologic prophylaxis include: • Active bleeding (GI bleeding, cerebral hemorrhage, retroperitoneal bleeding) • Documented bleeding risk • GI bleed • Risk of bleeding • Hemorrhage • Patients on continuous IV heparin therapy within 24 hours before or after surgery • Thrombocytopenia • Patient refusal If a patient has contraindications to pharmacologic prophylaxis, the patient is eligible for mechanical prophylaxis devices unless there are documented reasons for not administering mechanical devices. Reasons for not administering mechanical prophylaxis include: • Bilateral amputee • Bilateral lower extremity trauma • Patients on continuous IV heparin therapy within 24 hours before or after surgery • Patient refusal Clinical Effectiveness Department Version 5.0, Revised: 1-2013 21 Franciscan Surgical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m INPATIENT SURGICAL CARE IMPROVEMENT PROJECT (SCIP) (page 2) SURGICAL CARE IMPROVEMENT PROJECT (SCIP) Explanation and/or contraindications must be documented in the medical record Prophylactic Antibiotics Discontinued within 24 Hours after anesthesia End Time (48 Hours for CABG/ Cardiac Surgeries) Antibiotics must be discontinued within 24 hours of the anesthesia end time as documented on the anesthesia record (if anesthesia end time is not documented on the anesthesia record use the “To PACU” time). If antibiotics are continued beyond 24 hours (48 hours for cardiac/CABG cases) there must be explicit documentation stating why the antibiotic is still needed. Must document “possible infection” or “suspected infection” or an actual infection. Documentation of symptoms such as fever or increased WBC is not sufficient documentation to abstract a postoperative infection that warrants continuation of prophylactic antibiotics. Types of infections that are acceptable for continuation of antibiotics (must be documented): • Necrotic/ischemic/infarcted bowel • Abscess • Necrosis • Acute abdomen • Osteomyelitis • Aspiration pneumonia • Other documented infection • Bloodstream infection • Penetrating abdominal trauma • Bone infection • Perforation of bowel • Cellulitis • Purulence/pus • Crohn's disease • Pneumonia or other lung infection • Endometritis • Sepsis • Fecal contamination • Surgical site or wound infection • Free air in abdomen • Ulcerative colitis • Gangrene • Urinary tract infection (UTI) • H. pylori Not acceptable for continuation of antibiotics: • Avascular necrosis • Fungal infections • Bacteria in urine (Bacteriuria) • History of MRSA • “carditis” (such as pericarditis) • History of MRSA without mention of infection • History of infection • Colonized MRSA • Viral infections 22 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Surgical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m INPATIENT SURGICAL CARE IMPROVEMENT PROJECT (SCIP) (page 3) SURGICAL CARE IMPROVEMENT PROJECT (SCIP) Explanation and/or contraindications must be documented in the medical record SURGERY PATIENTS ON BETA-BLOCKER THERAPY PRIOR TO ARRIVAL WHO RECEIVED A BETA-BLOCKER DURING THE PERIOPERATIVE PERIOD The perioperative period for the SCIP cardiac measures is defined as 24 hours prior to surgical incision through POD 2. If a beta-blocker is listed as a home or current medication, it must be continued during the perioperative period unless there is explicit documentation stating reason for not administering (e.g., heart rate less than 50 bpm or other reason documented by Physician/APN/PA or Pharmacist). "Hold PO meds" or "NPO-hold meds" are not acceptable reasons for not administering beta-blockers postoperatively. If it is documented that the patient took a beta-blocker prior to arrival, there must be a date and a time to indicate when the last dose of the beta-blocker was taken. Clinical Effectiveness Department Version 5.0, Revised: 1-2013 23 Franciscan Surgical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m INPATIENT VENOUS THROMBOEMBOLISM (VTE) (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) VTE QUALITY INDICATORS Explanation and/or contraindications must be documented in the medical record VTE RISK ASSESSMENT AND APPROPRIATE PROPHYLAXIs Begun Applies to: • Medical and surgical patients upon hospital admission • ALL patients upon admission / transfer to ICU Key Points: • Documentation must be completed within 1 day of admission, surgery, or transfer to ICU • Both pharmacologic and mechanical prophylaxis must be addressed. If one type of prophylaxis is contraindicated (with reason documented), the other type of prophylaxis must be used unless a contraindication is explicitly documented as well. (e.g. ‘Active GI bleeding- LMWH contraindicated’. The patient would still require mechanical prophylaxis.) Reasons for not administering any pharmacologic or mechanical prophylaxis: • Patient at low risk for VTE • Explicit documentation that patient doesn’t need VTE prophylaxis • Patient / Family refusal ONLY Acceptable Oral Factor Xa Inhibitor Indications: • History of hip replacement surgery (not fracture) • History of knee replacement surgery • History of/current finding of Atrial Fibrillation or Atrial Flutter (except when terminated within 8 weeks following CABG) • Past/current history of treatment for VTE ANTICOAGULATION OVERLAP THERAPy Key Points: • If warfarin prescribed during hospitalization or at discharge, parenteral anticoagulation (IV, SQ) AND warfarin must be administered on the same calendar day or documented reason why not • Must be on overlap therapy for at least 5 days, until INR ≥ 2, before parenteral therapy is discontinued. If less than 5 days since overlap therapy begun, or INR < 2, patient must be discharged on both medications. Reasons for not administering overlap therapy: • Surgical procedure • Bleeding complications • Other reasons explicitly documented by Physician/APN/PA or Pharmacist 24 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Surgical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m INPATIENT VENOUS THROMBOEMBOLISM (VTE) (page 2) VTE QUALITY INDICATORS Explanation and/or contraindications must be documented in the medical record ANTICOAGULATION OVERLAP THERAPy (cont.) Reasons for discontinuation of parenteral therapy: • Bleeding risk • ‘High’ INR value, supratherapeutic • Severe anemia • Active bleeding • Not a candidate for long-term anticoagulation • Previously on warfarin • Received blood during this timeframe • Scheduled for surgery • Thrombocytopenia • Patient/Caregiver refusal • Other reasons explicitly documented by Physician/APN/PA or Pharmacist COMPLETE WARFARIN THERAPY DISCHARGE INSTRUCTIONS All four elements must be addressed within the medical record: • Compliance issues • Importance of taking warfarin as instructed • Importance of monitoring warfarin with scheduled PT/INR blood draws • Dietary Advice • A ‘consistent amount’ of foods with Vitamin K rather than avoidance should be advised • Avoid major changes in dietary habits, or notify health professional before changing habits • Follow-up Monitoring • Information about plans to monitor warfarin post-discharge (i.e. ‘Follow-up with Coumadin clinic in 1 week’) • Potential for Adverse Drug Reactions and Interactions • Diet and medications can affect the PT/INR level • Do not take or discontinue any medication or over-the-counter medication except on the advice of the Physician or Pharmacist •Warfarin increases the risk of bleeding Clinical Effectiveness Department Version 5.0, Revised: 1-2013 25 Franciscan Surgical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m STROKE (CMS Specifications Manual 4.2b—Discharges between 1-1-13 and 12-31-13) STROKE Quality Indicators Explanation and/or contraindications must be documented in the medical record VTE Prophylaxis given the day of or the day after hospital admission (ischemic and hemorrhagic) • • • Reasons for not administering must be explicitly documented such as “Active GI bleed – LMWH contraindicated” Documentation that patient is ambulating without mention of VTE prophylaxis is insufficient Stroke patients require a documented reason for not administering another form of prophylaxis when graduated compression stockings are the ONLY form of VTE prophylaxis administered Antithrombotic therapy prescribed at hospital discharge – anticoagulant and antiplatelet drugs (Ischemic) • • • All discharge medication documentation available in the chart will be taken into account unless the documentation is contradictory If documentation is contradictory, it will be considered “unable to determine” which will result in a variance The antithrombotic must be listed by name and not by medication class Anticoagulation Therapy for Atrial Fibrillation/Flutter prescribed at hospital discharge (Ischemic) • • All discharge medication documentation available in the chart will be taken into account unless the documentation is contradictory If documentation is contradictory, it will be considered “unable to determine” which will result in a variance Thrombolytic Therapy for acute ischemic stroke patients who arrive within 2 hours of time last know well and IV tPA initiated within 3 hours • • Reasons for not initiating IV thrombolytic therapy must be explicitly documented by a Physician/APN/PA or Pharmacist Nursing may document patient/family refusal, NIHSS score of zero or initiation of IV thrombolytic at a transferring hospital 26 Clinical Effectiveness Department Version 5.0, Revised: 1-2013 Franciscan Surgical Quality Indicators CMS/The Joint Commission E d u c at i o n F o r m Stroke (page 2) STROKE Quality Indicators Explanation and/or contraindications must be documented in the medical record Antithrombotic Therapy by End of Hospital Day 2 (Ischemic) • • Reason for not administering antithrombotic therapy must be dated/timed prior to end of hospital day 2 and explicitly documented by a Physician/APN/PA or Pharmacist Nursing may document patient/family refusal but it must be documented in the timeframe of arrival to end of hospital day 2 Discharged on Statin Medication (Ischemic) • • • All discharge medication documentation available in the chart will be taken into account unless the documentation is contradictory If documentation is contradictory, it will be considered “unable to determine” which will result in a variance The statin must be listed by name and not by medication class Stroke Education (Ischemic and hemorrhagic) Documentation that the patient or caregiver was given educational materials during the hospital stay addressing all of the following: • Activation of emergency medical system • Follow up after discharge (must be specific with provider name and appointment) • Medications prescribed at discharge (Home Medication List must match with Discharge MedRec and Discharge Summary) • Risk factors for stroke •Warning signs and symptoms of stroke Assessed for Rehabilitation services (Ischemic and hemorrhagic) • • Assessment for rehabilitation services must be completed by a qualified provider (excluding nursing) Documentation must be stated in the context of rehabilitation services such as “Patient returned to prior level of function, rehabilitation not indicated at this time” or “Symptoms resolved – no rehab needed” Clinical Effectiveness Department Version 5.0, Revised: 1-2013 27